Multiline treatment of advanced squamous cell carcinoma of the lung: A case report and review of the literature

Figure 4 Images from computed tomography showing the tumor response up to the fourth-line therapy of NVB + Endo. A: Imaging performed on May 17, 2016, after seven cycles of nab-PC therapy; B: On December 26, 2016, the disease was classified as partial remission; C: On April 17, 2017, the disease was classified as progressive; D: On April 27, 2017, the tumor was found to have a response to radiation therapy in the right lung (DT = 50 Gy/5F). Nab-PC: Nab-paclitaxel; NVB + Endo: 25 mg/m² vinorelbine on days 1 and 8, and 30 mg endostar on days 1-7.